Lamotriginum [Latin]
Brand names,
Lamotriginum [Latin]
Analogs
Lamotriginum [Latin]
Brand Names Mixture
Lamotriginum [Latin]
Chemical_Formula
C9H7Cl2N5
Lamotriginum [Latin]
RX_link
http://www.rxlist.com/cgi/generic/lamotrigine.htm
Lamotriginum [Latin]
fda sheet
Lamotriginum [Latin]
msds (material safety sheet)
Lamotriginum [Latin]
Synthesis Reference
M. G. Baxter et al., Eur. pat. Appl. 21,121 (1981 to Wellcome Foundation); D. A. Sawyer et al., U.S. pat. 4,602,017 (1986)
Lamotriginum [Latin]
Molecular Weight
256.091 g/mol
Lamotriginum [Latin]
Melting Point
216-218 oC (uncorr)
Lamotriginum [Latin]
H2O Solubility
No information avaliable
Lamotriginum [Latin]
State
Solid
Lamotriginum [Latin]
LogP
1.497
Lamotriginum [Latin]
Dosage Forms
Tablet; Chewable
Lamotriginum [Latin]
Indication
For the adjunctive treatment of partial seizures in epilepsy and generalized seizures of Lennox-Gastaut syndrome; For the maintenance treatment of Bipolar I Disorder
Lamotriginum [Latin]
Pharmacology
Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically unrelated to existing antiepileptic drugs. Lamotrigine is also used in the treatment of depression and bipolar disorder. Lamotrigine is thought to exert its anticonvulsant effect by stabilizing presynaptic neuronal membranes. Lamotrigine inhibits sodium currents by selectively binding to the inactivated state of the sodium channel and subsequently suppresses the release of the excilatory amino acid, glutamate.
Lamotriginum [Latin]
Absorption
98%
Lamotriginum [Latin]
side effects and Toxicity
LD50=250 (mg/kg) (in rat, mice); LD50>640 orally (mg/kg) (in rat, mice) (Sawyer); Decreased level of consciousness, coma, delayed heartbeat, increased seizures, lack of coordination, rolling eyeballs
Lamotriginum [Latin]
Patient Information
Lamotriginum [Latin]
Organisms Affected
Humans and other mammals